What SEC filings does Cognition Therapeutics, Inc. submit to the SEC?

Cognition Therapeutics, Inc. (CGTX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CGTX?

A Form 4 for CGTX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Cognition Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CGTX?

The 10-K is Cognition Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CGTX SEC filings directly on EDGAR?

You can view all historical Cognition Therapeutics, Inc. filings on the SEC EDGAR company page for CGTX. Each filing card on this page links directly to the original SEC document.

How often does Cognition Therapeutics, Inc. file with the SEC?

Cognition Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CGTX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CGTX SEC Filing News — Cognition Therapeutics, Inc.

Latest SEC filings for Cognition Therapeutics, Inc. (CGTX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-07.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mi…

Sector: Healthcare Industry: Biotechnology Market Cap: $69.2M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CGTX currently lean bullish. Of the 20 displayed SEC filing records, 3 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 9 insider transactions (Form 4) in this period.

CGTX Filing Activity Snapshot 2026-03-02 — 2026-08-07

Insider Transactions (Form 4)

3 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$11.3K

Doyle John Brendan (Chief Financial Officer) · 2026-04-20

10,000 shares · Form 4

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Cognition Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 5 compensation award, 3 open-market purchase and 1 tax withholding. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×5: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×3: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Tax withholding ×1: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

Khattar Jack A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Khattar Jack A. (Director) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

Monia Brett P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Monia Brett P (Director) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

Wallace Peggy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Wallace Peggy (Director) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

RICHSTONE ELLEN B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: RICHSTONE ELLEN B (Director) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

Fletcher Aaron G.L. (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Fletcher Aaron G.L. (Director, 10% Owner) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-05-04

CGTX insider Form 4 filed for equity award, exercise, or tax withholding

Doyle John Brendan (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	8,567	$1.28	$11.0K

Filing: Form 4 (Insider Transaction) Insider: Doyle John Brendan (Chief Financial Officer) Shares: 8,567

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

CGTX insider Doyle John Brendan (Chief Financial Officer) bought 10,000 shares (~$11.3K)

Doyle John Brendan, listed as Chief Financial Officer at COGNITION THERAPEUTICS INC, reported an open-market purchase of 10,000 CGTX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$1.13	$11.3K

Filing: Form 4 (Insider Transaction) Insider: Doyle John Brendan (Chief Financial Officer) Shares: 10,000 Est. Value: $11.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

CGTX insider Ricciardi Lisa (Director, CEO & President) bought 9,175 shares (~$10.1K)

Ricciardi Lisa, listed as Director, CEO & President at COGNITION THERAPEUTICS INC, reported an open-market purchase of 9,175 CGTX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	9,175	$1.10	$10.1K

Filing: Form 4 (Insider Transaction) Insider: Ricciardi Lisa (Director, CEO & President) Shares: 9,175 Est. Value: $10.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

CGTX insider Caggiano Anthony (Chief Medical Officer) bought 10,000 shares (~$11.1K)

Caggiano Anthony, listed as Chief Medical Officer at COGNITION THERAPEUTICS INC, reported an open-market purchase of 10,000 CGTX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$1.11	$11.1K

Filing: Form 4 (Insider Transaction) Insider: Caggiano Anthony (Chief Medical Officer) Shares: 10,000 Est. Value: $11.1K

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Cognition Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06